Precision medicine for the treatment of severe pneumonia in intensive care

Expert Review of Respiratory Medicine

Volumn 10, Issue 3, 2016, Pages 297-316

  Rello, Jordi ^a,b,c   Perez, Antonio ^a,b  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c Clinical Research and Innovation in Pneumonia and Sepsis (CRIPS)   (Spain)

Author keywords

adjunctive therapy; antibiotic therapy; bacterial load; personalized medicine; pneumonia; Precision medicine; sepsis

Indexed keywords

AERUCIN; ANTIBIOTIC AGENT; ASN 100; BACTERIAL DNA; BACTERIAL TOXIN; IC 43; KB 001; LIPOSOME; MEDI 3902; MEDI 4893; MONOCLONAL ANTIBODY; PANOBACUMAB; POLYSACCHARIDE VACCINE; SALVECIN; SAR 279356; SM 17220; STEROID; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; BACTERIAL VACCINE;

ANTIBIOTIC THERAPY; BACTERIAL LOAD; BACTERIOPHAGE; COMMUNITY ACQUIRED PNEUMONIA; DISEASE SEVERITY; EXPERIMENTAL THERAPY; HUMAN; IMMUNOMODULATION; IMMUNOPHENOTYPING; INTENSIVE CARE; METABOLOMICS; OUTCOME ASSESSMENT; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY VIRUS; REVIEW; SEVERE COMMUNITY ACQUIRED PNEUMONIA; STEM CELL; ADVERSE EFFECTS; COMMUNITY-ACQUIRED INFECTIONS; INTENSIVE CARE UNIT; MICROBIOLOGY; MORTALITY; PNEUMONIA, BACTERIAL; PNEUMONIA, VIRAL; PROCEDURES; RISK FACTOR; SEVERITY OF ILLNESS INDEX; STANDARDS; TREATMENT OUTCOME; VIROLOGY;

ANTI-BACTERIAL AGENTS; BACTERIAL VACCINES; COMMUNITY-ACQUIRED INFECTIONS; CRITICAL CARE; HUMANS; INTENSIVE CARE UNITS; PNEUMONIA, BACTERIAL; PNEUMONIA, VIRAL; PRACTICE GUIDELINES AS TOPIC; PRECISION MEDICINE; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84960448055     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/17476348.2016.1144477     Document Type: Review

References (176)

1. Osler W. The principles and practice of medicine: designed for the use of practitioners and students of medicine. New York (NY): D. Appleton and Company; 1892.
2. Fine MJ, Smith MA, Carson CA, et al Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. JAMA. 1996;275:134-141.
3. Bauer TT, Welte T, Ernen C, et al Cost analyses of community-acquired pneumonia from the hospital perspective. Chest. 2005;128:2238-2246.
4. Colice GL, Morley MA, Asche C, et al Treatment costs of community-acquired pneumonia in an employed population. Chest. 2004;125:2140-2145.
5. Angus DC, Marrie TJ, Obrosky DS, et al. Severe community-acquired pneumonia. Use of intensive care services and evaluation of American and British Thoracic Society diagnostic criteria. Am J Respir Crit Care Med. 2002;166:717-723.
6. Ewig S, Ruiz M, Mensa J, et al Severe communityacquired pneumonia. Assessment of severity criteria. Am J Respir Crit Care Med. 1998;158:1102-1108.
7. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997;336:243-250.
8. Rodríguez A, Mendia A, Sirvent J-M, et al. Combination antibiotic therapy improves survival in patients with community-acquired pneumonia and shock. Crit Care Med. 2007;35:1493-1498.
9. Pachon J, Prados MD, Capote F, et al. Severe communityacquired pneumonia. Etiology, prognosis, and treatment. Am Rev Respir Dis. 1990;142:369-373.
10. Torres A, Serra-Batlles J, Ferrer A, et al. Severe community-acquired pneumonia. Epidemiology and prognostic factors. Am Rev Respir Dis. 1991;144:312-318.
11. Rautanen A, Mills TC, Gordon AC, et al. Genome-wide association study of survival from sepsis due to pneumonia: an observational cohort study. Lancet Respir Med. 2015;3:53-60. Epub 2015 Dec 18. doi:10.1016/S2213-2600(14)70290-5.
12. Singanayagam A, Chalmers JD, Hill AT. Severity assessment in community-acquired pneumonia: a review. QJM. 2009;102:379-388.
13. Tang CM, Macfarlane JT. Early management of younger adults dying of community acquired pneumonia. Respir Med. 1993;87:289-294.
14. Neill AM, Martin IR, Weir R, et al. Community acquired pneumonia: aetiology and usefulness of severity criteria on admission. Thorax. 1996;51:1010-1016.
15. McQuillan P, Pilkington S, Allan A, et al. Confidential inquiry into quality of care before admission to intensive care. BMJ. 1998;316:1853-1858.
16. Man SY, Lee N, Ip M, et al. Prospective comparison of three predictive rules for assessing severity of community-acquired pneumonia in Hong Kong. Thorax. 2007;62:348-353.
17. Aujesky D, Auble TE, Yealy DM, et al. Prospective comparison of three validated prediction rules for prognosis in community acquired pneumonia. Am J Med. 2005;118:384-392.
18. Chalmers JD, Mandal P, Singanayagam A, et al. Severity assessment tools to guide ICU admission in communityacquired pneumonia: systematic review and meta-analysis. Intensive Care Med. 2011;37:1409-1420.
19. Lim WS, Smith DL, Wise MP, et al. British Thoracic Society community acquired pneumonia guideline and the NICE pneumonia guideline: how they fit together. Thorax. 2015;70:698-700.
20. Chalmers JD, Singanayagam A, Hill AT. Systolic blood pressure is superior to other haemodynamic predictors of outcome in community acquired pneumonia. Thorax. 2008;63:698702.
21. Lim WS, Van Der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003;58:377382.
22. Capelastegui A, España PP, Quintana JM, et al. Validation of a predictive rule for the management of communityacquired pneumonia. Eur Respir J. 2006;27:151-157.
23. Bauer TT, Ewig S, Marre R, et al. CRB65 predicts death from community-acquired pneumonia. J Intern Med. 2006;260:93-101.
24. Ewig S, Welte T. CRB65 for the assessment of pneumonia severity: who could ask for more? Thorax. 2008;63:665-666.
25. Shindo Y, Sato S, Maruyama E, et al. Comparison of severity scoring systems A-DROP and CURB-65 for community-acquired pneumonia. Respirology. 2008 Sep;13 (5):731-735. doi:10.1111/j.1440-1843.2008.01329.x.
26. Restrepo MI, Mortensen EM, Rello J, et al. Late admission to the ICU in patients with community-acquired pneumonia is associated with higher mortality. Chest. 2010;137:552-557.
27. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases society of America/American thoracic society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44:S27-72.
28. Niederman MS, Mandell LA, Anzueto A, et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med. 2001;163:1730-1754.
29. Charles PGP, Wolfe R, Whitby M, et al. SMART-COP: a tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia. Clin Infect Dis. 2008;47:375-384.
30. Chalmers JD, Singanayagam A, Hill AT. Predicting the need for mechanical ventilation and/or inotropic support for young adults admitted to the hospital with community-acquired pneumonia. Clin Infect Dis. 2008;47:1571-1574.
31. Brown SM, Jones BE, Jephson AR, et al. Validation of the infectious disease society of America/American thoracic society 2007 guidelines for severe community-acquired pneumonia. Crit Care Med. 2009;37:3010-3016.
32. Buising KL, Thursky KA, Black JF, et al. A prospective comparison of severity scores for identifying patients with severe community acquired pneumonia: reconsidering what is meant by severe pneumonia. Thorax. 2006;61:419-224.
33. Chalmers JD, Taylor JK, Mandal P, et al. Validation of the infectious diseases society of America/American thoratic society minor criteria for intensive care unit admission in community-acquired pneumonia patients without major criteria or contraindications to intensive care unit care. Clin Infect Dis. 2011;53:503-511.
34. España PP, Capelastegui A, Gorordo I, et al. Development and validation of a clinical prediction rule for severe community-acquired pneumonia. Am J Resp Crit Care Med. 2006;174:1249-1256.
35. Yandiola PP, Capelastegui A, Quintana J, et al. Prospective comparison of severity scores for predicting clinically relevant outcomes for patients hospitalized with community-acquired pneumonia. Chest. 2009;135:1572-1579.
36. Rello J, Rodriguez A, Lisboa T, et al. PIRO score for community-acquired pneumonia: a new prediction rule for assessment of severity in intensive care unit patients with community-acquired pneumonia. Crit Care Med. 2009;37:456-462.
37. Mueller C, Laule-Kilian K, Scholer A, et al. B-type natriuretic peptide for risk stratification in community-acquired pneumonia. J Intern Med. 2005;258:391-393.
38. Christ-Crain M, Breidthardt T, Stolz D, et al. Use of B-type natriuretic peptide in the risk stratification of communityacquired pneumonia. J Intern Med. 2008;264:166-176.
39. Menendez R, Martínez R, Reyes S, et al. Biomarkers improve mortality prediction by prognostic scales in community-acquired pneumonia. Thorax. 2009;64:587-591.
40. Christ-Crain M, Morgenthaler NG, Stolz D, et al. Pro-adrenomedullin to predict severity and outcome in community-acquired pneumonia. Critical Care. 2006;10:R96-R103.
41. Masia M, Gutierrez F, Shum C, et al. Usefulness of procalcitonin levels in community-acquired pneumonia according to the patients outcome research team Pneumonia Severity Index. Chest. 2005;128:2223-2229.
42. Kruger S, Ewig S, Marre R, et al. Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB65 classes. Eur Respir J. 2008;31:349-355.
43. Müller B, Harbarth S, Stolz D, et al. Diagnostic and prognostic accuracy of clinical and laboratory parameters in community-acquired pneumonia. BMC Infect Dis. 2007;7:10.
44. Lee JH, Kim J, Kim K, et al. Albumin and C-reactive protein have prognostic significance in patients with community-acquired pneumonia. J Crit Care. 2011;26:287-294.
45. Huang D, Weissfeld LA, Kellum JA, et al. Risk prediction with procalcitonin and clinical rules in communityacquired pneumonia. Ann Emerg Med. 2008;52:48-58.
46. Almirall J, Bolíbar I, Toran P, et al. Contribution of C-reactive protein to the diagnosis and assessment of severity of community-acquired pneumonia. Chest. 2004;125:1335-1342.
47. Hohenthal U, Hurme S, Helenius H, et al. Utility of C-reactive protein in assessing the disease severity and complications of community-acquired pneumonia. Clin Microbiol Infect. 2009;15:1026-1032.
48. Müller B, Morgenthaler N, Stolz D, et al. Circulating levels of copeptin, a novel biomarker, in lower respiratory tract infections. Eur J Clin Invest. 2007;37:145-152.
49. Christ-Crain M, Stolz D, Jutla S, et al. Free and total cortisol levels as predictors of severity and outcome in community-acquired pneumonia. Am J Respir Crit Care Med. 2007;176:913-920.
50. Müller B, Süess E, Schuetz P, et al. Circulating levels of pro-atrial natriuretic peptide in lower respiratory tract infections. J Intern Med. 2006;260:568-576.
51. Krüger S, Papassotiriou J, Marre R, et al. Pro-atrial natriuretic peptide and pro-vasopressin to predict severity and prognosis in community-acquired pneumonia: results from the German Competence Network CAPNETZ. Intensive Care Med. 2007;33:2069-2078.
52. Chalmers JD, Singanayagam A, Hill AT. C-reactive protein is an independent predictor of severity in communityacquired pneumonia. Am J Med. 2008;121:219-225.
53. Querol-Ribelles JM, Tenias JM, Grau E, et al. Plasma d-dimer levels correlate with outcomes in patients with community-acquired pneumonia. Chest. 2004;126:1087-1092.
54. Chalmers JD, Singanayagam A, Scally C, et al. Admission D-dimer can identify low-risk patients with communityacquired pneumonia. Ann Emerg Med. 2009;53:633-638.
55. Gotoh S, Nishimura N, Takahashi O, et al. Adrenal function in patients with community-acquired pneumonia. Eur Respir J. 2008;31:1268-1273.
56. Kolditz M, Halank M, Schulte-Hubbert B, et al. Adrenal function is related to prognosis in moderate communityacquired pneumonia. Eur Respir J. 2010;36:615-621.
57. Hirata Y, Mitaka C, Sato K, et al. Increased circulating adrenomedullin, a novel vasodilatory peptide, in sepsis. J Clin Endocrinol Metab. 1996;81:1449-1453.
58. Huang DT, Angus DC, Pugh NA, et al. Proadrenomedullin in emergency department patients with communityacquired pneumonia. Ann Emerg Med. 2008;52(Suppl 4):S41.
59. Schuetz P, Wolbers M, Christ-Crain M, et al. Prohormones for prediction of adverse medical outcome in community-acquired pneumonia and lower respiratory tract infections. Crit Care. 2010;14(3):R106. doi:10.1186/cc9055.
60. Prat C, Lacoma A, Dominguez J, et al. Midregional proatrial natriuretic peptide as a prognostic marker in pneumonia. J Infect. 2007;55:400-407.
61. Masia M, Papassotiriou J, Morgenthaler NG, et al. Midregional pro-A-type natriuretic peptide and carboxyterminal provasopressin may predict prognosis in community-acquired pneumonia. Clin Chem. 2007;53:2193-2201.
62. Claessens Y-E, Mathevon T, Kierzek G, et al. Accuracy of C-reactive protein, procalcitonin and mid-regional proatrial natriuretic peptide to guide site of care of community-acquired pneumonia. Intensive Care Med. 2010;36:799-809.
63. Uchida T, Shirasawa M, Ware LB, et al. Receptor for advanced glycation endproducts is a marker of type I cell injury in acute lung injury. Am J Respir Crit Care Med. 2006;173:1008-1015.
64. Angus DC, Yang L, Kong L, et al. Circulating high-mobility group box 1 (HMGB1) concentrations are elevated in both uncomplicated pneumonia and pneumonia with severe sepsis. Crit Care Med. 2007;35:1061-1067.
65. Gibot S, Cravoisy A, Levy B, et al. Soluble triggering receptor expressed on myeloid cells and the diagnosis of pneumonia. N Engl J Med. 2004;350:451-458.
66. Oshansky CM, Gartland AJ, Wong-S-S, et al. Mucosal immune responses predict clinical outcomes during influenza infection independently of age and viral load. Am J Respir Crit Care Med. 2014;189:449-462.
67. Landsman JB. Bacteriaemia and prognosis in lobar pneumonia: the results of quantitative blood culture in pneumococcus pneumonia. Glasgow Med J. 1952;33:33-45.
68. Christie IM. Bacteraemia in lobar pneumonia. The Lancet. 1933;222:804-805.
69. Carrol ED, Guiver M, Nkhoma S, et al. High pneumococcal DNA loads are associated with mortality in Malawian children with invasive pneumococcal disease. Pediatr Infect Dis J. 2007;26:416-422.
70. Peters RP, Van Agtmael MA, Gierveld S, et al. Quantitative detection of Staphylococcus aureus and Enterococcus faecalis DNA in blood to diagnose bacteremia in patients in the intensive care unit. J Clin Microbiol. 2007;45:3641-3646.
71. Ho Y-C, Chang S-C, Lin S-R, et al. High levels of mecA DNA detected by a quantitative realtime PCR assay are associated with mortality in patients with methicillinresistant Staphylococcus aureus bacteremia. J Clin Microbio. 2009;47:1443-1451.
72. Peters RP, De Boer RF, Schuurman T, et al. Streptococcus pneumoniae DNA load in blood as a marker of infection in patients with community-acquired pneumonia. J Clin Microbiol. 2009;47:3308-3312.
73. Chuang YC, Chang SC, Wang WK. High and Increasing Oxa-51 DNA load predict mortality in Acinetobacter baumannii bacteremia: implication for pathogenesis and evaluation of therapy. PLoS One. 2010;5(11):e14133.
74. Munoz-Almagro GS, Selva L, et al. DNA bacterial load in children and adolescents with pneumococcal pneumonia and empyema. Eur J Clin Microbiol Infect Dis. 2011;30:327-335.
75. Kim DM, Jung SI, Jang HC, et al. Vibrio vulnificus DNA load and mortality. J Clin Microbiol. 2011;49:413-415.
76. Rello J, Lisboa T, Lujan M, et al. Severity of pneumococcal pneumonia associated with genomic bacterial load. Chest. 2009;136:832-840.
77. Ferrer R, Artigas A, Suarez D, et al. Effectiveness of treatments for severe sepsis: a prospective, multicenter, observational study. Am J Respir Crit Care Med. 2009;180:861-866.
78. Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006;34:1589-1596.
79. Meehan TP, Fine MJ, Krumeholtz HM, et al. Quality of care, process, and outcomes in elderly patients with pneumonia. JAMA. 1997;278:2080-2084.
80. Houck PM, Bratzler DW, Nsa W, et al. Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia. Arch Intern Med. 2004;164:637-644.
81. Menendez R, Torres A, Reyes S, et al. Initial management of pneumonia and sepsis. Factors associated with improved outcome. Eur Respir J. 2012;39(1):156-162. doi:10.1183/09031936.00188710
82. Marrie TJ, Wu L. Factors influencing in-hospital mortality in community-acquired pneumonia: a prospective study of patients not initially admitted to the ICU. Chest. 2005;127:1260-1270.
83. Benenson R, Magalski A, Cavanaugh S, et al. Effects of a pneumonia clinical pathway on time to antibiotic treatment, length of stay, and mortality. Acad Emerg Med. 1999;6:1243-1248.
84. Silber SH, Garret C, Singh R, et al. Early administration of antibiotics does not shorten time to clinical stability in patients with moderate-to-severe community-acquired pneumonia. Chest. 2003;124:1798-1804.
85. Battleman DS, Callahan M, Thaler HT. Rapid antibiotic delivery and appropriate antibiotic selection reduce length of hospital stay of patients with communityacquired pneumonia: link between quality of care and resource utilization. Arch Intern Med. 2002;162:682.
86. Ziss DR, Stowers A, Feild C. Community-acquired pneumonia: compliance with centers for Medicare and Medicaid services, national guidelines, and factors associated with outcome. South Med J. 2003;96:949-959.
87. Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult lower respiratory tract infections. Clin Microbiol Infect. 2011;17(Suppl. 6):E1-E59.
88. Mufson MA, Stanek RJ. Bacteremic pneumococcal pneumonia in one American city: a 20-year longitudinal study, 1978-1997. Am J Med. 1999;107:34S-43S.
89. Baddour LM, Yu VL, Klugman KP, et al. Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am J Respir Crit Care Med. 2004;170:440-444.
90. Waterer GW, Somes GW, Wunderink RG. Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med. 2001;161:1837-1842.
91. Martinez JA, Horcajada JP, Almela M, et al. Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis. 2003;36:389-395.
92. Weiss K, Low DE, Cortes L, et al. Clinical characteristics at initial presentation and impact of dual therapy on the outcome of bacteremic Streptococcus pneumoniae pneumonia in adults. Can Respir J. 2004;11:589-593.
93. Ortqvist A, Hedlund J, Grillner L, et al. Aetiology, outcome and prognostic factors in community-acquired pneumonia requiring hospitalization. Eur Respir J. 1990;3:1105-1113.
94. Lieberman D, Schlaeffer F, Boldur I, et al. Multiple pathogens in adult patients admitted with communityacquired pneumonia: a one year prospective study of 346 consecutive patients. Thorax. 1996;51:179-184.
95. Lim WS, Macfarlane JT, Boswell TC, et al. Study of community acquired pneumonia aetiology (SCAPA) in adults admitted to hospital: implications for management guidelines. Thorax. 2001;56:296-301.
96. Jokinen C, Heiskanen L, Juvonen H, et al. Microbial etiology of community-acquired pneumonia in the adult population of 4 municipalities in eastern Finland. Clin Infect Dis. 2001;32:1141-1154.
97. Arnold FW, Summersgill JT, La Joie AS, et al. A worldwide perspective of atypical pathogens in communityacquired pneumonia. Am J Respir Crit Care Med. 2007;175:1086-1093.
98. Metersky ML, Ma A, Houck PM, et al. Antibiotics for bacteremic pneumonia: improved outcomes with macrolides but not fluoroquinolones. Chest. 2007;131:466-473.
99. Martin-Loeches I, Lisboa T, Rodriguez A, et al. Combination antibiotic therapy with macrolides improves survival in intubated patients with community-acquired pneumonia. Intensive Care Med. 2010;36:612-620.
100. Postma DF, Van Werkhoven CH, Van Elden LH, et al. Antibiotic treatment strategies for community-acquired pneumonia in adults. N Engl J Med. 2015;372:1312-1323.
101. Giamarellos-Bourboulis EJ. Immunomodulatory therapies for sepsis: unexpected effects with macrolides. Int J Antimicrob Agents. 2008;32(Suppl 1):S39-43.
102. Giamarellos-Bourboulis EJ, Baziaka F, Antonopoulou A, et al. Clarithromycin coadministered with amikacin attenuates systemic inflammation in experimental sepsis with Escherichia coli. Int J Antimicrob Agents. 2005;25:168-172.
103. Ikegaya S, Inai K, Iwasaki H, et al. Azithromycin reduces tumor necrosis factor-alpha production in lipopolysaccharide-stimulated THP-1 monocytic cells by modification of stress response and p38 MAPK pathway. J Chemother. 2009;21:396-402.
104. Gao X, Ray R, Xiao Y, et al. Macrolide antibiotics improve chemotactic and phagocytic capacity as well as reduce inflammation in sulfur mustard-exposed monocytes. Pulm Pharmacol Ther. 2010;23:97-106.
105. Anderson R, Steel HC, Cockeran R, et al. J Clarithromycin alone and in combination with ceftriaxone inhibits the production of pneumolysin by both macrolide-susceptible and macrolideresistant strains of Streptococcus pneumoniae. J Antimicrob Chemother. 2007;59:224-229.
106. Burgess DS, Lewis JS. Effect of macrolides as part of initial empiric therapy on medical outcomes for hospitalized patients with community acquired pneumonia. Clin Ther. 2000;22:872878.
107. Paul M, Nielsen AD, Gafter-Gvili A, et al The need for macrolides in hospitalised community-acquired pneumonia: propensity analysis. Eur Respir J. 2007;30:525-531.
108. Dwyer R, Ortqvist A, Aufwerber E, et al. Addition of amacrolide to a ss-lactam in bacteremic pneumococcal pneumonia. Eur J Clin Microbiol Infect Dis. 2006;25:518-521.
109. Loh L-C, Quah S-Y, Khoo S-K, et al. Addition of macrolide in treating adult hospitalized community-acquired pneumonia. Respirology. 2005;10:371-377.
110. Roig J, Rello J. Legionnaire's disease: a rational approach to therapy. J Antimicrob Chemother. 2003;51:1119-1129.
111. Plouffe JF, Breiman RF, Fields BS, et al. Azithromycin in the treatment of Legionella pneumonia requiring hospitalization. Clin Infect Dis. 2003;37:1475-1480.
112. Sabria M, Pedro-Botet ML, Gomez J, et al. Fluoroquinolones vs macrolides in the treatment of Legionnaires disease. Chest. 2005;128:1401-1405.
113. Yu VL, Greenberg RN, Zadeikis N, et al. Levofloxacin efficacy in the treatment of community-acquired legionellosis. Chest. 2004;125:2135-2139.
114. Dean NC, Silver MP, Bateman KA, et al. Decreased mortality after implementation of a treatment guideline for community-acquired pneumonia. Am J Med. 2001;110:451-457.
115. Garcia Vazquez E, Mensa J, Martinez JA, et al. Lower mortality among patients with community-acquired pneumonia treated with a macrolide plus a beta-lactam agent versus a betalactam agent alone. Eur J Clin Microbiol Infect Dis. 2005;24:190-195.
116. Mortensen EM, Restrepo M, Anzueto A, et al. Effects of guideline-concordant antimicrobial therapy on mortality among patients with community-acquired pneumonia. Am J Med. 2004;117:726-731.
117. Restrepo MI, Mortensen EM, Anzueto A, et al. Mortality in monotherapy versus combination therapy in severe community-acquired pneumonia: a systematic review. Chest. 2003;124(4S):190S.
118. Menendez R, Torres A, Zalacain R, et al. Guidelines for the treatment of community-acquired pneumonia: predictors of adherence and outcome. Am J Respir Crit Care Med. 2005;172:757-762.
119. Arnold FW, La Joie AS, Brock GN, et al. Improving outcomes in elderly patients with community-acquired pneumonia by adhering to national guidelines: community-acquired pneumonia organization international cohort study results. Arch Intern Med. 2009;169 (16):1515.
120. Shorr AF, Bodi M, Rodriguez A, et al. Impact of antibiotic guideline compliance on duration of mechanical ventilation in critically ill patients with community-acquired pneumonia. Chest. 2006;130:93-100.
121. Puren AJ, Feldman C, Savage N, et al. Patterns of cytokine expression in community-acquired pneumonia. Chest. 1995;107:1342-1349.
122. Monton C, Ewig S, Torres A, et al. Role of glucocorticoids on inflammatory response in nonimmunosuppressed patients with pneumonia: a pilot study. Eur Respir J. 1999;14:218-220.
123. Fernandez-Serrano S, Dorca J, Coromines M, et al. Molecular inflammatory responses measured in blood of patients with severe community-acquired pneumonia. Clin Diagn Lab Immunol. 2003;10:813-820.
124. Confalonieri M, Urbino R, Potena A, et al. Hydrocortisone infusion for severe communityacquired pneumonia: a preliminary randomized study. Am J Respir Crit Care Med. 2005;171:242248.
125. Siemieniuk RA, Meade MO, Alonso Coello P, et al. Corticosteroid therapy for patients hospitalized with community-acquired pneumonia: a systematic review and meta-analysis. Ann Intern Med. 2015;163:519-528.
126. Wan YD, Sun TW, Liu ZQ, et al. Efficacy and safety of corticosteroids for community-acquired pneumonia: A systematic review and meta-analysis. Chest. 2016;149 (1):209-219. doi:10.1378/chest.15-1733
127. Mikami M, Suzuki M, Kitagawa H, et al. Efficacy of corticosteroids in the treatment of community-acquired pneumonia requiring hospitalization. Lung. 2007;185:249-255.
128. Garcia-Vidal C, Calbo E, Pascual V, et al. Effects of systemic steroids in patients with severe communityacquired pneumonia. Eur Respir J. 2007;30:951-956.
129. Horita N, et al Adjunctive systemic corticosteroids for hospitalized community-acquired pneumonia: systematic review and meta-analysis 2015 update. Sci Rep. 2015;5:14061.
130. Fernandez-Serrano S, Dorca J, Garcia-Vidal C, et al. Effects of corticosteroids on the clinical course of communityacquired pneumonia: a randomized controlled trial. Critical Care. 2011;15:R96.
131. Mortensen EM, Pugh MJ, Copeland LA, et al. Impact of statins and angiotensin-converting enzyme inhibitors on mortality of subjects hospitalised with pneumonia. Eur Respir J. 2008;31:611-617.
132. Schlienger RG, Fedson DS, Jick SS, et al. Statins and the risk of pneumonia: a populationbased, nested case-control study. Pharmacotherapy. 2007;27:325-332.
133. Majumdar SR, McAlister FA, Eurich DT, et al. Statins and outcomes in patients admitted to hospital with community acquired pneumonia: population based prospective cohort study. BMJ. 2006;333:999.
134. Laterre P-F, Opal SM, Abraham E, et al. A clinical evaluation committee assessment of recombinant human tissue factor pathway inhibitor (tifacogin) in patients with severe communityacquired pneumonia. Crit Care. 2009;13:R36.
135. Meisel C, Schefold JC, Pschowski R, et al. Granulocyte macrophage colony-stimulating factor to reverse sepsisassociated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial. Am J Respir Crit Care Med. 2009;180:640-648.
136. Confalonieri M, Potena A, Carbone G, et al. Acute respiratory failure in patients with severe community-acquired pneumonia. A prospective randomized evaluation of noninvasive ventilation. Am J Respir Crit Care Med. 1999;160:1585-1591.
137. Ferrer M, Esquinas A, Leon M, et al., et al. Noninvasive ventilation in severe hypoxemic respiratory failure: a randomized clinical trial. Am J Respir Crit Care Med. 2003;168:1438-1444.
138. Antonelli M, Conti G, Esquinas A, et al. A multiple-center survey on the use in clinical practice of noninvasive ventilation as a first-line intervention for acute respiratory distress syndrome. Crit Care Med. 2007;35:18-25.
139. Opal SM, Calandra T. Antibiotic usage and resistance: gaining or losing ground on infections in critically ill patients? JAMA. 2009;302:2367-2368.
140. Huet O, Chin-Dusting JP. Septic shock: desperately seeking treatment. Clin Sci (Lond). 2014;126:31-39.
141. Morton B, Pennington SH, Gordon SB. Immunomodulatory adjuvant therapy in severe community-acquired pneumonia. Expert Rev Respir Med. 2014;8:587-596.
142. Steel HC, Cockeran R, Anderson R, et al. Overview of community-acquired pneumonia and the role of inflammatory mechanisms in the immunopathogenesis of severe pneumococcal disease. Mediators Inflamm. 2013;2013:490346. doi:10.1155/2013/490346.
143. Roux D, Pier GB, Skurnik D. Magic bullets for the 21st century: the reemergence of immunotherapy for multiand pan-resistant microbes. J Antimicrob Chemother. 2012;67:27852787.
144. Yu VL, Chiou CC, Feldman C, et al. An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome. Clin Infect Dis. 2003;37:230-237.
145. Adkins I, Holubova J, Kosova M, et al. Bacteria and their toxins tamed for immunotherapy. Curr Pharm Biotechnol. 2012;13:1446-1473.
146. Los FC, Randis TM, Aroian RV, et al. Role of pore-forming toxins in bacterial infectious diseases. Microbiol Mol Biol Rev. 2013;77:173-207.
147. Marriott HM, Mitchell TJ, Dockrell DH. Pneumolysin: a double-edged sword during the hostpathogen interaction. Curr Mol Med. 2008;8:497-509.
148. Hurley JC. Towards clinical applications of anti-endotoxin antibodies; a re-appraisal of the disconnect. Toxins (Basel). 2013;5:2589-2620.
149. Horn MP, Zuercher AW, Imboden MA, et al. Preclinical in vitro and in vivo characterization of the fully human monoclonal IgM antibody KBPA101 specific for Pseudomonas aeruginosa serotype IATS-O11. Antimicrob Agents Chemother. 2010;54:2338-2344.
150. Que Y-A, Lazar H, Wolff M, et al. Assessment of panobacumab as adjunctive immunotherapy for the treatment of nosocomial Pseudomonas aeruginosa pneumonia. Eur J Clin Microbiol Infect Dis. 2014;33:1861-1867.
151. François B, Luyt C-E, Dugard A, et al. Safety and pharmacokinetics of an anti-PcrV PEGylated monoclonal antibody fragment in mechanically ventilated patients colonized with Pseudomonas aeruginosa: a randomized, double-blind, placebo-controlled trial. Crit Care Med. 2012;40(8):2320-2326.
152. Milla CE, Chmiel JF, Accurso FJ, et al. Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection. Pediatr Pulmonol. 2014;49:650-658.
153. Kollberg H, Carlander D, Olesen H, et al. Oral administration of specific yolk antibodies (IgY) may prevent Pseudomonas aeruginosa infections in patients with cystic fibrosis: a phase I feasibility study. Pediatr Pulmonol. 2003;35:433-440.
154. Harrison FJ, Rohm D, Kohzuki T, et al. Pharmacokinetics, tolerability, and preliminary efficacy of human anti-Pseudomonas aeruginosa monoclonal antibodies in pneumonia and burn infection patients. Hybridoma. 1997;16:413-420.
155. Lu Q, Rouby J-J, Laterre P-F, et al. Pharmacokinetics and safety of panobacumab: specific adjunctive immunotherapy in critical patients with nosocomial Pseudomonas aeruginosa O11 pneumonia. J Antimicrob Chemother. 2011;66:1110-1116.
156. Oganesyan V, Peng L, Damschroder MM, et al. Mechanisms of neutralization of a human anti-α-toxin antibody. J Biol Chem. 2014;289:29874-29880.
157. https://www.clinicaltrials.gov/ct2/show/NCT01589185? term=aridis&rank=2
158. Savoia D. New perspectives in the management of Pseudomonas aeruginosa infections. Future Microbiol. 2014;9:917-928.
159. https://www.clinicaltrials.gov/ct2/show/NCT01455675? term=igy&rank=1
160. Di Giandomenico A, Keller AE, Gao C, et al. A multifunctional bispecific antibody protects against Pseudomonas aeruginosa. Sci Transl Med. 2014;6:262ra155.
161. http://www.drugdevelopment-technology.com/news/newsaridis-begins-phase-i-trial-of-aerucinmonoclonalantibody-to-treat-acute-pneumonia-4541705
162. Rouha H, Badarau A, Visram ZC, et al. Five birds, one stone: neutralization of α-hemolysin and 4 bi-component leukocidins of Staphylococcus aureus with a single human monoclonal antibody. MAbs. 2015;7(1):243-254. doi:10.4161/19420862.2014.985132.
163. Grimwood K, Kyd JM, Owen SJ, et al. Vaccination against respiratory Pseudomonas aeruginosa infection. Hum Vaccin Immunother. 2015;11:14-20.
164. Vincent J-L. Vaccine development and passive immunization for Pseudomonas aeruginosa in critically ill patients: a clinical update. Future Microbiol. 2014;9:457-463.
165. Feldman CL, Anderson R. Bacteraemic pneumococcal pneumonia: current therapeutic options. Drugs. 2011;71:131-153.
166. Chang H-I, Yeh M-K. Clinical development of liposomebased drugs: formulation, characterization, and therapeutic efficacy. Int J Nanomedicine. 2012;7:49-60.
167. Azeredo Da Silveira S, Perez A. Liposomes as novel antiinfectives targeting bacterial virulence factors? Expert Rev Anti Infect Ther. 2015;13:531-533.
168. Henry BD, Neill DR, Becker KA, et al. Engineered liposomes sequester bacterial exotoxins and protect from severe invasive infections in mice. Nat Biotechnol. 2015;33:81-88.
169. Lombardo E, Van Der Poll T, Dela Rosa O, et al. Mesenchymal stem cells as a therapeutic tool to treat sepsis. World J Stem Cells. 2015;7:368-379.
170. Matsuda A, Jacob A, Wu R, et al. Novel therapeutic targets for sepsis: regulation of exaggerated inflammatory responses. J Nippon Med Sch. 2012;79:4-18.
171. Zhu Y-G, Hao Q, Monsel A, et al. Adult stem cells for acute lung injury: remaining questions and concerns. Respirology. 2013;18:744-756.
172. Wittebole X, De Roock S, Opal SM. A historical overview of bacteriophage therapy as an alternative to antibiotics for the treatment of bacterial pathogens. Virulence. 2014;5:226-235.
173. Pérez-Carrasco M, Lagunes L, Antón A, et al. Influenza infection in the intensive care unit. Four years after the pandemic. Enferm Infecc Microbiol Clin. 2015 May 26;pii:S0213005X(15)00151-2. doi:10.1016/j.eimc.2015.04.004.
174. Pedro-Botet ML, Burgos J, Lunan M, et al. Impact of pandemic influenza 2009 H1N1pandemic on invasive pneumococcal infection in adults. Eur J Clin Microbiol Infect Dis. 2014;46:185-192.
175. Choi SH, Huh JW, Hong SB, et al. Clinical characteristics and outcomes of severe rhinovirusassociated pneumonia identified by bronchoscopic bronchoalveolar lavage in adults: comparison with severe influenza virus-associated pneumonia. J Clin Virol. 2015;62:41-47. Epub 2014 Nov 15 doi:10.1016/j.jcv.2014.11.010.
176. Rello J, Lisboa T, Wunderink RG. Severe communityacquired pneumonia and PIRO: a new paradigm of management. Curr Infect Dis Rep. 2009;11:343-348.